Moelis & Company LLC is the operating subsidiary of Moelis & Company, an independent global investment bank founded in 2007 and headquartered in New York. The firm provides strategic and financial advisory services to corporations, financial sponsors, and governments, including mergers and acquisitions, divestitures, joint ventures, restructurings and recapitalizations, fairness opinions, and capital markets advisory across debt and equity.
Moelis advises clients across sectors relevant to the chemical value chain, such as chemicals, specialty materials, life sciences, energy, and industrials. Its teams support portfolio optimization, carve-outs, cross-border transactions, liability management, and other corporate finance situations for both public and private companies. The firm operates globally, offering independent advice and transaction execution across market cycles.
Adds BPL-003 (mebufotenin benzoate intranasal) and VLS-01 (DMT buccal); upfront $6.75/share plus up to $2.50/share CVR tied to development, regulatory and DEA-rescheduling milestones.
Ventyx's small molecule pipeline targets chronic inflammation in cardiometabolic, neurodegenerative, and inflammatory diseases, aiming for improved efficacy and safety.
